Export 257 results:
[ Author
Filters: First Letter Of Last Name is C [Clear All Filters]
“Clinical trails referral resource. Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab”, Oncology, vol. 15, pp. 1026-36, 2001.
, “Mortality Risk in Children after Renal Allograft Failure: A NAPRTCS Study”, Pediatr Nephrol, vol. 25, pp. 2517-2522, 2010.
, “Evaluation of observation-fused regional air quality model results for population air pollution exposure estimation.”, Sci Total Environ, vol. 485-486, pp. 563-574, 2014.
, “Mortality risk in children after renal allograft failure: a NAPRTCS study.”, Pediatr Nephrol, vol. 25, no. 12, pp. 2517-22, 2010.
, “Does allograft failure impact infection risk on peritoneal dialysis: a North American Pediatric Renal Trials and Collaborative Studies Study.”, Clin J Am Soc Nephrol, vol. 7, no. 1, pp. 153-7, 2012.
, “Does Allograft Failure Impact Infection Risk on Peritoneal Dialysis: A North American Pediatric Renal Trials and Collaborative Studies Study”, Clin J Am Soc Nephrol, vol. 7, pp. 153-157, 2012.
, “Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.”, J Clin Oncol, vol. 24, no. 21, pp. 3354-60, 2006.
, “Evaluation of Observation-Fused Regional Air Quality Model Results for Population Air Pollution Exposure Estimation”, Sci Total Environ, vol. 485-486, pp. 563-574, 2014.
, “Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research.”, J Allergy Clin Immunol Pract, vol. 6, no. 5, pp. 1534-1544.e5, 2018.
, “Pre-transplant blood transfusion and renal allograft outcome: a report of the North American Pediatric Renal Transplant Cooperative Study.”, Pediatr Transplant, vol. 1, no. 1, pp. 22-8, 1997.
, “Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan.”, Int J Drug Policy, vol. 43, pp. 1-6, 2017.
, “Safety and Tolerability of Chikungunya Virus-Like Particle Vaccine in Healthy Adults: A Phase 1 Dose-Escalation Trial”, Lancet, vol. 384, pp. 2046-2052, 2014.
, “Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32.”, Ophthalmology, vol. 118, no. 11, pp. 2113-9, 2011.
, “Proteomic Analysis of Human Immune Responses to Live-Attenuated Tularemia Vaccine.”, Vaccines (Basel), vol. 8, no. 3, 2020.
, “Demographic and Dietary Characteristics of the Age-Related Eye Disease Study 2 (AREDS2) Participants and Their Associations With Age-Related Macular Degeneration (AMD)”, in Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, 2010.
, “Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.”, Lancet, vol. 384, no. 9959, pp. 2046-52, 2014.
, “SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.”, Ophthalmology, vol. 118, no. 7, pp. 1364-72, 2011.
, “SCORE Study Report #11: Incidences of Neovascular Events in Eyes with Retinal Vein Occlusion”, Ophthalmology, vol. 118, pp. 1364-1372, 2011.
, “Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial.”, JAMA, vol. 311, no. 16, pp. 1652-60, 2014.
, “Lorazepam vs Diazepam for Pediatric Status Epilepticus: A Randomized Clinical Trial”, JAMA, vol. 311, pp. 1652-1660, 2014.
, “Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.”, Clin Vaccine Immunol, vol. 23, no. 4, pp. 315-25, 2016.
, “Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.”, PLoS Negl Trop Dis, vol. 12, no. 4, p. e0006442, 2018.
, “Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.”, Vaccine, vol. 24, no. 4, pp. 417-25, 2006.
, “Phase I Clinical Trial Safety of DNA- and Modified Virus Ankara-Vectored Human Immunodeficiency Virus Type 1 (HIV-1) Vaccines Administered Alone and in a Prime-Boost Regime to healthy HIV-1 Uninfected Volunteers”, Vaccine, vol. 24, pp. 417-425, 2006.
, “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.”, J Infect Dis, vol. 194, no. 12, pp. 1638-49, 2006.
,